Susceptibility Trends of Zoliflodacin against Multidrug-Resistant *Neisseria gonorrhoeae* Clinical Isolates in Nanjing, China, 2014 to 2018

Wenjing Le,a Xiaohong Su,a Xiangdi Lou,a Xuechun Li,a Xiangdong Gong,a Baoxi Wang,a,b Caroline A. Genco,c John P. Mueller,d Peter A. Rice*e

aSTD Clinic, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
bDepartment of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
cDepartment of Immunology, School of Medicine, Tufts University, Boston, Massachusetts, USA
dEntasis Therapeutics, Waltham, Massachusetts, USA
eDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

**ABSTRACT** Previously, we reported the potent activity of a novel spiropyrimidine-trione, zoliflodacin, against *Neisseria gonorrhoeae* isolates collected in 2013 from symptomatic men in Nanjing, China. Here, we investigated trends of susceptibilities to zoliflodacin in 986 isolates collected from men between 2014 and 2018. *N. gonorrhoeae* isolates were tested for susceptibility to zoliflodacin and seven other antibiotics. Mutations in the *gyrA*, *gyrB*, *parC*, *parE*, and *mtrR* genes were determined by PCR and sequencing. The MICs of zoliflodacin ranged from \(0.002\) to \(0.25\) mg/liter; the overall MIC\(_{50}\) and MIC\(_{90}\) were \(0.06\) mg/liter and \(0.125\) mg/liter, respectively, in 2018, increasing 2-fold from 2014. However, the percentage of isolates with lower zoliflodacin MICs declined in each year sequentially, while the percentage with higher MICs increased yearly \((P \leq 0.00001)\). All isolates were susceptible to spectinomycin but resistant to ciprofloxacin \((\geq 1\) mg/liter); 21.2% (209/986) were resistant to azithromycin \((\geq 1\) mg/liter), 43.4% (428/986) were penicillinase-producing *N. gonorrhoeae* (PPNG), 26.9% (265/986) were tetracycline-resistant *N. gonorrhoeae* (TRNG), and 19.4% (191/986) were multidrug-resistant (MDR) isolates. 202 isolates with the lowest \((\leq 0.002\) to \(0.015\) mg/liter) and highest (0.125 to 0.25 mg/liter) zoliflodacin MICs were quinolone resistant with double or triple mutations in *gyrA*; 193/202 (95.5%) also had mutations in *parC*. There were no D429N/A and/or K450T mutations in GyrB identified in the 143 isolates with higher zoliflodacin MICs; an S467N mutation in GyrB was identified in one isolate. We report that zoliflodacin continues to have excellent in vitro activity against clinical gonococcal isolates, including those with high-level resistance to ciprofloxacin, azithromycin, and extended-spectrum cephalosporins.

**KEYWORDS** *N. gonorrhoeae*, DNA gyrase, zoliflodacin, susceptibility
been reported in China (4), Japan (5), Australia (6), European countries (7), and the United States (8), and isolates with high-level resistance to ceftriaxone have been identified in Japan, Australia, France, Spain, Denmark, Canada, Ireland, and China (9–11).

The reported prevalences of azithromycin-resistant *N. gonorrhoeae* isolates are 18.6% in China (4), 14.5% in Japan (5), 6.2% in Australia (6), 7.5% in 25 European countries (7), 4.6% in the United States (8), and 6.1% in western Africa (12). The first documented case that failed treatment with the recommended dual therapy was reported from the United Kingdom in 2016 (13), and the first gonococcal isolates (the A2543 clone) with combined ceftriaxone resistance plus high-level azithromycin resistance were identified in the United Kingdom (14) and Australia (15) in 2018.

Increased antimicrobial resistance (AMR) in *N. gonorrhoeae* poses an emerging global public health threat of untreatable gonococcal infections. New oral antimicrobial agents with activity against *N. gonorrhoeae* are needed urgently. The WHO includes *N. gonorrhoeae* on its list of “priority pathogens” that require new antibiotics for treatment (16), and the U.S. CDC has designated drug-resistant *N. gonorrhoeae* an urgent threat (17). Zoliﬂodacin (also known as AZD0914 and ETX0914) is a novel spiro-pyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with broad-spectrum in vitro activity against Gram-positive and fastidious Gram-negative organisms, including *N. gonorrhoeae* (18, 19). A recent multicenter, randomized, phase 2 clinical trial demonstrated that zoliﬂodacin was effective in treating gonococcal urogenital and rectal infections and supports a larger, more definitive study of zoliﬂodacin for the treatment of uncomplicated gonorrhea (20). We showed previously that zoliﬂodacin was highly effective against clinical isolates of *N. gonorrhoeae in vitro*, including high-level ciprofloxacin-resistant and multidrug-resistant (MDR) isolates collected in 2013 in Nanjing, China (21). Here, in vitro activities and trends of zoliﬂodacin susceptibilities were determined for clinical gonococcal isolates (including multidrug-resistant isolates) collected between 2014 and 2018 in Nanjing. Mutations in the quinolone-resistance-determining regions (QRDRs) of the *gyrA*, *parC*, *gyrB*, *parE*, and *mtrR* genes were also determined for isolates across the zoliﬂodacin MIC distribution range.

**RESULTS**

**Susceptibilities to zoliﬂodacin and other antimicrobials.** Susceptibilities (MICs) of *N. gonorrhoeae* to zoliﬂodacin and seven antimicrobials previously or currently used for the treatment of gonorrhea are summarized for the 986 clinical isolates in Table 1. All isolates except one were inhibited by $\leq 0.125$ mg/liter of zoliﬂodacin (the remaining isolate had an MIC of 0.25 mg/liter). MICs to zoliﬂodacin ranged from $\leq 0.002$ to 0.25 mg/liter overall, with MIC$_{50}$ and MIC$_{90}$ values of 0.06 mg/liter and 0.125 mg/liter, respectively. One hundred forty-three (14.5%) isolates had zoliﬂodacin MICs at the upper end of the distribution range (0.125 to 0.25 mg/liter), and 59 (6%) isolates had MICs at the lower end of the MIC distribution range ($\leq 0.002$ to 0.015 mg/liter). The

---

**TABLE 1** Susceptibilities and MICs of zoliﬂodacin and seven antimicrobials previously or currently used for the treatment of gonorrhea against 986 clinical *N. gonorrhoeae* isolates

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>No. (%) of isolates</th>
<th>MIC (mg/liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Susceptible Intermediate Resistant</td>
<td>Range</td>
</tr>
<tr>
<td>Zoliﬂodacin</td>
<td>986 (100)</td>
<td>$\leq 0.002$ to 0.25</td>
</tr>
<tr>
<td>Penicillin G</td>
<td>0</td>
<td>171 (17.3)</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>4 (0.4)</td>
<td>150 (15.2)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0</td>
<td>986 (100)</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>551 (55.9)</td>
<td>226 (22.9)</td>
</tr>
<tr>
<td>Spectinomycin</td>
<td>986 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Cefixime</td>
<td>948 (96.1)</td>
<td>38 (3.9)</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>984 (99.8)</td>
<td>2 (0.2)</td>
</tr>
</tbody>
</table>
percentage of isolates with an MIC of 0.03 mg/liter to zolidofacin declined in each year sequentially ($\chi^2 = 82.237; P = 0.000$), while the percentage with MICs of 0.06 and 0.125 mg/liter increased correspondingly ($\chi^2 = 20.739$ and 41.717, respectively; $P \leq 0.00001$ by a chi-square test for linear trends), as shown in Fig. 1. Overall, the proportion of isolates with zolidofacin MICs of 0.125 to 0.25 mg/liter increased from 3.1% (6/197) in 2014 to 23.0% (47/204) in 2018 ($\chi^2 = 43.112; P < 0.0001$).

All 986 isolates were resistant to ciprofloxacin; 777 (78.8%) showed high-level resistance ($\geq 16$ mg/liter) (22). During the 5-year study period, the annual percentage of ciprofloxacin-resistant isolates at each MIC point (from 1 mg/liter to $\geq 16$ mg/liter) did not shift in either direction in the 5-year period. MICs of gonococcal isolates for zolidofacin were lower than those for ciprofloxacin ($P < 0.0001$), with a median difference of at least 267-fold. Four hundred twenty-eight isolates (43.4%) were penicillinase-producing N. gonorrhoeae (PPNG), and 265 (26.9%) were tetracycline-resistant N. gonorrhoeae (TRNG) isolates. The percentage of penicillin-resistant isolates increased from 70% to 86.3% over the 5 years ($\chi^2 = 17.641; P < 0.0001$). Although all isolates were susceptible to spectinomycin, the percentage of isolates with lower spectinomycin MICs (8 mg/liter and 16 mg/liter) declined ($\chi^2 = 16.35$ and 93.71; $P = 0.0001$ and $P < 0.0001$, respectively), while the percentage with higher MICs (32 mg/liter) increased over the 5 years ($\chi^2 = 112.514; P < 0.0001$).

Two hundred nine (21.2%) isolates were resistant to azithromycin (MIC $\geq 1$ mg/liter), and 62 (6.3%) displayed high-level resistance (MIC $\geq 256$ mg/liter). The percentage of isolates with lower azithromycin MICs (0.06 mg/liter and 0.125 mg/liter) increased over the 5 years ($\chi^2 = 16.916$ and 22.099, respectively; $P < 0.0001$), while the percentage with higher MICs (0.5 mg/liter and $\geq 1,024$ mg/liter) declined yearly ($\chi^2 = 15.403$ and 12.268, respectively; $P < 0.001$). Overall, the percentage of azithromycin-resistant isolates (MIC $\geq 1$ mg/liter) decreased from 27.9% to 15.2% over the 5 years, and the percentage of azithromycin-susceptible isolates increased from 72.1% to 84.8% ($\chi^2 = 14.618; P < 0.001$). One hundred fifty-eight isolates (15.2%) exhibited decreased susceptibility (MIC of 0.125 to 0.25 mg/liter [$n = 156$]) or resistance (MIC=1 mg/liter [$n = 2$]) to ceftriaxone, and 102 isolates (10.1%) displayed decreased susceptibility (MIC of 0.25 mg/liter [$n = 64$]) or resistance (MIC of 0.5 mg/liter [$n = 36$] and MIC of $>2$ mg/liter [$n = 2$]) to cefixime. The percentage of isolates with lower ceftriaxone MICs ($\leq 0.03$ mg/liter) declined in each year sequentially ($\chi^2 = 10.512; P < 0.01$), while the percentage with higher MICs (0.06 mg/liter and 0.125 mg/liter) increased yearly ($\chi^2 = 10.18$ and 4.231; $P < 0.01$ and $P < 0.05$, respectively). The percentage of isolates with lower cefixime MICs (0.015 mg/liter and 0.03 mg/liter) declined ($\chi^2 = 23.324$ and
Characterization of amino acid substitutions in GyrA, GyrB, ParC, and ParE. All 202 isolates tested were ciprofloxacin resistant (MICs of 2 to ≥16 mg/liter). All isolates had double or triple mutations in the gyrA gene. Both the S91F and D95A/G/N/Y amino acid substitutions in GyrA were identified in the 202 isolates. Sixteen (11.2%) of the isolates in the higher zoliflodacin MIC distribution group and two (3.4%) in the lower-MIC group also had an additional A92P amino acid substitution in GyrA. ParC substitutions were observed in 97.2% of the isolates in the higher zoliflodacin MIC distribution group and in 91.5% of the isolates in the lower-MIC group. Single, double, and triple ParC substitutions were identified in 114 (79.7%), 22 (15.4%), and 3 (2.1%) of the isolates in the higher-MIC distribution group and in 66.1%, 25.4%, and 0% of the isolates in the lower-MIC group, respectively. The amino acid substitution at position S87 in ParC, including S87C, S87I, S87N, or S87R, was present in 79.7% of isolates in the higher-MIC distribution group and in 66.1%, 25.4%, and 0% of the isolates in the lower-MIC group, respectively. The amino acid substitution at position S87 in ParC, including S87C, S87I, S87N, or S87R, was present in 79.7% of isolates in the higher-MIC distribution group and in 66.1%, 25.4%, and 0% of the isolates in the lower-MIC group, respectively.

Mutations in mtrR. A number of single or multiple mutations were identified in the 202 isolates with the lowest (≤0.002 to 0.015 mg/liter) and highest (0.125 to 0.25 mg/liter) zoliflodacin MICs. These included an adenosine (A) deletion in the mtrR promoter region and mutations in the mtrR coding region that resulted in amino acid changes in MtrR: A39T, A40D, G45D, F62L, D79N, T86A, H105Y, and E117K mutations, singly or in combination (see Table S2 in the supplemental material). A total of 175 (86.6%) isolates carried the A deletion: 48 (81.4%) in the low zoliflodacin MIC group and 127 (88.8%) in the high zoliflodacin MIC group (P = 0.2346). There were no significant differences in the rates of individual mutations (singly or combined) in MtrR accompanied (or not) by an A deletion in the promoter region, except for an H105Y mutation accompanied by an A deletion in the promoter, which accounted for 62.7% (37/59) of isolates with low zoliflodacin MICs and 41.3% (59/143) of isolates in the high zoliflodacin MIC group (P < 0.01) (Table S2).

DISCUSSION

We determined susceptibility trends in the in vitro antibacterial activities of zoliflodacin and seven other antimicrobial agents against 986 clinical gonococcal isolates collected over a 5-year period (2014 to 2018). The 986 gonococcal isolates were susceptible to zoliflodacin, and all were resistant to ciprofloxacin. Nearly one-quarter of the
isolates were resistant to azithromycin or were TRNG isolates. More than 40% were PPNG isolates, and just under 20% were MDR isolates. All 986 isolates had zolidodacin MICs below the breakpoint (MIC ≤ 0.5 mg/liter) that has been proposed, guided by clinical efficacy (20). Similar to other reports (19, 23), zolidodacin exhibited an MIC range of 0.002 to 0.25 mg/liter, and there was no correlation between zolidodacin MICs at the upper end of the MIC range and ciprofloxacin resistance (19, 24, 25).

Furthermore, zolidodacin exhibited low MICs (0.03 and 0.06 mg/liter) in two isolates that were fully resistant to ceftriaxone and ceftixime. A modest temporal shift in the MICs to zolidodacin was observed over the 5-year period.

Zolidodacin is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor that prevents bacterial DNA biosynthesis and results in the accumulation of double-strand cleavages through a mechanism distinct from that in fluoroquinolones (1, 18, 24). In our study, all the ciprofloxacin-resistant zolidodacin-sensitive isolates tested displayed double or triple mutations in GyrA; 90% had additional amino acid substitutions in ParC.

In contrast to fluoroquinolones, zolidodacin inhibits the GyrB subunit of type II topoisomerase; specific mutations in GyrB can result in increased resistance to zolidodacin (24, 25). We did not find mutations such as D429N, D429A, or K450T alterations in GyrB, which have been identified in vitro and select for resistant mutants that result in zolidodacin MICs of 0.5 to 8 mg/liter (24, 25). However, we found that 4/143 (2.8%) gonococcal isolates at the upper end of the MIC distribution range (0.125 and 0.25 mg/liter) were resistant to azithromycin or were TRNG isolates. More than 40% were PPNG isolates, and just under 20% were MDR isolates. All 986 isolates had zolidodacin MICs below the breakpoint (MIC ≤ 0.5 mg/liter) that has been proposed, guided by clinical efficacy (20). Similar to other reports (19, 23), zolidodacin exhibited an MIC range of 0.002 to 0.25 mg/liter, and there was no correlation between zolidodacin MICs at the upper end of the MIC range and ciprofloxacin resistance (19, 24, 25). Furthermore, zolidodacin exhibited low MICs (0.03 and 0.06 mg/liter) in two isolates that were fully resistant to ceftriaxone and ceftixime. A modest temporal shift in the MICs to zolidodacin was observed over the 5-year period.

Zolidodacin is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor that prevents bacterial DNA biosynthesis and results in the accumulation of double-strand cleavages through a mechanism distinct from that in fluoroquinolones (1, 18, 24). In our study, all the ciprofloxacin-resistant zolidodacin-sensitive isolates tested displayed double or triple mutations in GyrA; 90% had additional amino acid substitutions in ParC.

In contrast to fluoroquinolones, zolidodacin inhibits the GyrB subunit of type II topoisomerase; specific mutations in GyrB can result in increased resistance to zolidodacin (24, 25). We did not find mutations such as D429N, D429A, or K450T alterations in GyrB, which have been identified in vitro and select for resistant mutants that result in zolidodacin MICs of 0.5 to 8 mg/liter (24, 25). However, we found that 4/143 (2.8%) gonococcal isolates at the upper end of the MIC distribution range (0.125 and 0.25 mg/liter) were resistant to azithromycin or were TRNG isolates. More than 40% were PPNG isolates, and just under 20% were MDR isolates. All 986 isolates had zolidodacin MICs below the breakpoint (MIC ≤ 0.5 mg/liter) that has been proposed, guided by clinical efficacy (20). Similar to other reports (19, 23), zolidodacin exhibited an MIC range of 0.002 to 0.25 mg/liter, and there was no correlation between zolidodacin MICs at the upper end of the MIC range and ciprofloxacin resistance (19, 24, 25). Furthermore, zolidodacin exhibited low MICs (0.03 and 0.06 mg/liter) in two isolates that were fully resistant to ceftriaxone and ceftixime. A modest temporal shift in the MICs to zolidodacin was observed over the 5-year period.

Zolidodacin is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor that prevents bacterial DNA biosynthesis and results in the accumulation of double-strand cleavages through a mechanism distinct from that in fluoroquinolones (1, 18, 24). In our study, all the ciprofloxacin-resistant zolidodacin-sensitive isolates tested displayed double or triple mutations in GyrA; 90% had additional amino acid substitutions in ParC.

In contrast to fluoroquinolones, zolidodacin inhibits the GyrB subunit of type II topoisomerase; specific mutations in GyrB can result in increased resistance to zolidodacin (24, 25). We did not find mutations such as D429N, D429A, or K450T alterations in GyrB, which have been identified in vitro and select for resistant mutants that result in zolidodacin MICs of 0.5 to 8 mg/liter (24, 25). However, we found that 4/143 (2.8%) gonococcal isolates at the upper end of the MIC distribution range (0.125 and 0.25 mg/liter) were resistant to azithromycin or were TRNG isolates. More than 40% were PPNG isolates, and just under 20% were MDR isolates. All 986 isolates had zolidodacin MICs below the breakpoint (MIC ≤ 0.5 mg/liter) that has been proposed, guided by clinical efficacy (20). Similar to other reports (19, 23), zolidodacin exhibited an MIC range of 0.002 to 0.25 mg/liter, and there was no correlation between zolidodacin MICs at the upper end of the MIC range and ciprofloxacin resistance (19, 24, 25). Furthermore, zolidodacin exhibited low MICs (0.03 and 0.06 mg/liter) in two isolates that were fully resistant to ceftriaxone and ceftixime. A modest temporal shift in the MICs to zolidodacin was observed over the 5-year period.

**Zolidodacin against Multidrug-Resistant Gonococci**

**Antimicrobial Agents and Chemotherapy**

March 2021 Volume 65 Issue 3 e00863-20 aac.asm.org

---

**TABLE 2** Comparison of amino acid substitutions in GyrA, GyrB, ParC, and ParE in isolates with lower zolidodacin MICs versus isolates with higher MICs

<table>
<thead>
<tr>
<th>Protein and amino acid substitution</th>
<th>Lower zolidodacin MIC group (n = 59)</th>
<th>Higher zolidodacin MIC group (n = 143)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GyrA</td>
<td>59 (100)</td>
<td>143 (100)</td>
<td>NA</td>
</tr>
<tr>
<td>S91F</td>
<td>59 (100)</td>
<td>143 (100)</td>
<td></td>
</tr>
<tr>
<td>D95A/G/N/Y</td>
<td>59 (100)</td>
<td>143 (100)</td>
<td></td>
</tr>
<tr>
<td>A92P</td>
<td>2 (3.39)</td>
<td>16 (11.19)</td>
<td>0.103</td>
</tr>
<tr>
<td>D80N</td>
<td>1 (1.69)</td>
<td>0</td>
<td>0.292</td>
</tr>
<tr>
<td>V81I</td>
<td>1 (1.69)</td>
<td>0</td>
<td>0.292</td>
</tr>
<tr>
<td>ParC</td>
<td>54 (91.53)</td>
<td>139 (97.20)</td>
<td>0.13</td>
</tr>
<tr>
<td>G85C/D/A</td>
<td>14 (23.73)</td>
<td>7 (4.90)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>D86N</td>
<td>3 (5.08)</td>
<td>20 (13.99)</td>
<td>0.088</td>
</tr>
<tr>
<td>S87C/I/N/R</td>
<td>48 (81.36)</td>
<td>114 (79.72)</td>
<td>0.943</td>
</tr>
<tr>
<td>S88P</td>
<td>1 (1.69)</td>
<td>10 (6.99)</td>
<td>0.181</td>
</tr>
<tr>
<td>A89T</td>
<td>1 (1.69)</td>
<td>1 (0.70)</td>
<td>0.499</td>
</tr>
<tr>
<td>E91G</td>
<td>2 (3.39)</td>
<td>7 (4.90)</td>
<td>1.000</td>
</tr>
<tr>
<td>G120R</td>
<td>0</td>
<td>2 (1.40)</td>
<td>1.000</td>
</tr>
<tr>
<td>A123V</td>
<td>0</td>
<td>3 (2.10)</td>
<td>0.557</td>
</tr>
<tr>
<td>A129V</td>
<td>0</td>
<td>3 (2.10)</td>
<td>0.557</td>
</tr>
<tr>
<td>GyrB</td>
<td>0</td>
<td>4 (2.80)</td>
<td>0.32</td>
</tr>
<tr>
<td>S467N</td>
<td>0</td>
<td>1 (0.70)</td>
<td>1.000</td>
</tr>
<tr>
<td>V470I</td>
<td>0</td>
<td>2 (1.40)</td>
<td>1.000</td>
</tr>
<tr>
<td>+480A</td>
<td>0</td>
<td>1 (0.70)</td>
<td>1.000</td>
</tr>
<tr>
<td>ParE</td>
<td>20 (33.90)</td>
<td>57 (39.86)</td>
<td>0.43</td>
</tr>
<tr>
<td>D437H/N</td>
<td>5 (8.47)</td>
<td>34 (23.78)</td>
<td>0.01</td>
</tr>
<tr>
<td>P456S</td>
<td>14 (23.73)</td>
<td>22 (15.38)</td>
<td>0.227</td>
</tr>
<tr>
<td>P469L</td>
<td>0</td>
<td>1 (0.70)</td>
<td>1.000</td>
</tr>
<tr>
<td>D425Y</td>
<td>1 (1.69)</td>
<td>0</td>
<td>0.292</td>
</tr>
<tr>
<td>L462I</td>
<td>1 (1.69)</td>
<td>0</td>
<td>0.292</td>
</tr>
</tbody>
</table>

* Denotes with zolidodacin MICs of ≤0.002 to 0.015 mg/liter.
* Denotes with zolidodacin MICs of 0.125 to 0.25 mg/liter.
* Determined by the χ² or Fisher exact test. NA, not applicable.
litter) harbored a GyrB mutation; however, the amino acid substitutions/insertions (S467N, V470I, or 480A) were not associated with resistance. An S467N amino acid substitution in GyrB, which did not result in reduced susceptibility to zoliflodacin, has been reported in a clinical gonococcal isolate (19). V470I or 480A mutations have not been reported previously in clinical isolates or in in vitro-selected resistant mutants.

Mutations in mtrR, which result in the overexpression of the MtrCDE efflux pump, can increase the efflux of antimicrobials and reduce susceptibility to numerous antimicrobials (1, 26). The MtrCDE efflux pump can also influence susceptibility to zoliflodacin (25). Inactivation of the MtrCDE efflux pump has been shown to decrease the MIC of zoliflodacin in *N. gonorrhoeae* strain H041 from 0.125 to 0.004 mg/liter (25). In our study, an adenine (A) deletion in the mtrR promoter and a number of mutations in MtrR (or both) were identified in isolates that possessed either lower or higher zoliflodacin MICs. A single H105Y amino acid substitution was the most common substitution present in MtrR; this change was identified in 50% of the isolates. The single H105Y amino acid substitution, which lies outside the known DNA binding domain of MtrR, is generally thought not to be involved in the active repressor function of MtrR; it has also been shown to be associated with *N. gonorrhoeae* isolates that are fully sensitive to ceftriaxone (27). One possibility is that the H105Y mutation may interfere with MtrR dimerization, resulting in a reduction of MtrR binding to target sequences (28).

Few studies have examined the impact of parE mutations on quinolone resistance in *N. gonorrhoeae* (29, 30). Clinical gonococcal isolates with P439S amino acid substitutions in ParE did not result in a significant increase in the MIC to ciprofloxacin (30, 31). The clinical relevance of the ParE mutations identified in our study is unclear.

In conclusion, zoliflodacin demonstrated potent *in vitro* antibacterial activity against a recent collection of clinical gonococcal isolates from China (2014 to 2018), including isolates with high-level resistance to ciprofloxacin, azithromycin, and extended-spectrum cephalosporins. Zoliflodacin MICs shifted upward temporally in the 5-year period in the absence of clinical use. These results confirm the lack of preexisting clinical resistance to zoliflodacin. Continued monitoring of antimicrobial susceptibility to zoliflodacin, a promising new oral antibacterial agent, for the treatment of uncomplicated gonorrhea is warranted.

**MATERIALS AND METHODS**

**Bacterial isolates.** From January 2014 to December 2018, a total of 986 gonococcal isolates were collected from male patients with symptomatic urethritis (urethral discharge and/or dysuria) attending the STD Clinic at the Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China. All men except one reported that they were heterosexual. Urethral exudates were collected with cotton swabs, immediately inoculated onto Thayer-Martin medium (Zhuhai DL Biotech, China), and cultured in candle jars at 36°C for 24 to 48 h. Gonococcal isolates were identified by colony morphology, Gram’s stain and oxidase testing, and growth on GC chocolate agar base (Difco, Detroit, MI) supplemented with 1% IsoVitaleX (Oxoid, USA). Gonococcal colonies were suspended in tryptone-based soy broth and frozen (−70°C) until used for antimicrobial testing.

**Antimicrobial susceptibility testing.** Zoliflodacin powder was provided by Entasis Therapeutics (Waltham, MA). The MICs (milligrams per liter) of *N. gonorrhoeae* isolates to zoliflodacin, penicillin, tetracycline, ciprofloxacin, spectinomycin, azithromycin, ceftizoxime, and ceftriaxone were determined by the agar dilution method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (32). ATCC 49226 and WHO reference strains F, G, L, O, and P were used as quality controls (QCs). The MIC ranges of zoliflodacin for QC strain ATCC 49226 were 0.125 to 0.25 mg/liter in each antimicrobial susceptibility testing run in this study, in accordance with the defined MIC QC ranges (0.06 to 0.5 mg/liter) for zoliflodacin (33). Criteria for decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/liter) and ceftizoxime (MIC ≥ 0.25 mg/liter) were defined by the WHO (34). Using CLSI (32) and EUCAST (35) (for azithromycin only) criteria, the following MIC breakpoints were used to ascertain resistance: ≥128 mg/liter for spectinomycin, ≥2 mg/liter for penicillin and tetracycline, and ≥1 mg/liter for ciprofloxacin and azithromycin. The breakpoint for zoliflodacin of ≥0.5 mg/liter was utilized as previously described (20). Multidrug-resistant (MDR) *N. gonorrhoeae* was defined as decreased susceptibility or resistance to extended-spectrum cephalosporins (ESCs) plus resistance to at least two of the following antimicrobials: penicillin, ciprofloxacin, and azithromycin (36, 37).

**Identification of gene mutations that resulted in amino acid substitutions in GyrA, GyrB, ParC, and ParE.** One hundred forty-three gonococcal isolates with zoliflodacin MICs (0.125 mg/liter and 0.25 mg/liter) at the upper end of the MIC distribution range and 59 isolates with lower zoliflodacin MICs (≤0.002 to 0.015 mg/liter) were selected for genetic resistance determinant studies. Mutations in the
quinolone-resistance-determining regions (QRDRs) of the gyrA, gyrB, parC, and parE genes were determined by PCR and DNA sequencing using primers described previously (38–40) (see Table S1 in the supplemental material). Genomic DNA was extracted from gonococcal isolates using a rapid bacterial genomic DNA isolation kit (DNA-EZ Reagents V All-DNA-Fast-Out; Sangon Biotech Co. Ltd., Shanghai, China). PCR amplification and sequencing of the genes were carried out by Nanjing Qingke Biotech Co. Ltd.

Evaluation of mutations in the mtrR gene. To identify mutations that potentially could cause enhanced expression of the MtrCDE efflux pump, mutations in the mtrR gene and promoter region were identified by PCR. Sequencing of mtr genes from 202 isolates was performed as described previously (27).

Data analysis. Chi-square (χ²) testing was used to compare the rates of resistance in different years, and a chi-square test for linear trends was used to assess the changes in the MICs and the proportion of isolates resistant to antibiotics. SPSS version 19.0 was used for statistical analysis; a P value of <.05 was considered statistically significant.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We thank Magnus Unemo for providing WHO reference strains.

This work was supported by the Chinese Grants from the Academy of Medical Sciences Initiative for Innovative Medicine (2016-I2M-3-021) and the U.S. National Institutes of Health (AI084048 and AI116999).

One author (John P. Mueller) is employed by the manufacturer of zoliflodacin but was not involved in the design or the execution of the study but rather in the writing/preparation of the manuscript. The other authors declare no conflicts.

REFERENCES


18. Huband MD, Bradford PA, Otterstrom LG, Basarab GS, Kutchke AC, ...
loci of Neisseria gonorrhoeae isolates suggests a new effective option for oral 

Ohnishi M, Unemo M. 2014. High in vitro susceptibility to the novel 
spiropyrimidinetrione ETX0914 among 873 contemporary clinical 
Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Che-

26. Golparian D, Shafer WM, Ohnishi M, Unemo M. 2014. Importance of multi-


High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemo-

24. Alm RA, Lahiri SD, Kutschke A, Ottersson LG, McLaughlin RE, Whiteaker JD, 

25. Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, 
Althaus CL, Unemo M. 2015. Genetic resistance determinants, in vitro 
time-kill curve analysis and pharmacodynamic functions for the novel to-

that alter the DNA-binding domain of the MtrR protein occur frequently in 

Fan J, Gao N, Mills SD, Mueller J, Sriman T, Thresher J, Walkup GK. 2015. In-
hibition of Neisseria gonorrhoeae type II topoisomerase by the novel spiro-

delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of 

for antimicrobial susceptibility testing: twenty-eighth informational sup-
mension M100. Clinical and Laboratory Standards Institute, Wayne, PA.

Determination of MIC quality control ranges for the novel gyrase inhibitor 

34. World Health Organization. 2012. Global action plan to control the spread 
and impact of antimicrobial resistance in Neisseria gonorrhoeae. World 
Health Organization, Geneva, Switzerland. https://www.who.int/antimicrobial 


health challenge of multidrug- and extensively drug-resistant Neisseria 

37. Clifton S, Bolt H, Mohammed H, Town K, Furugato M, Cole M, Campbell O, 
Neisseria gonorrhoeae in England and Wales between 2004 and 2015: 
analysis of annual cross-sectional surveillance surveys. J Antimicrob Che-

ance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resist-

39. Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Kawada Y, Ezaki T, 
Saito I. 1996. Uncommon occurrence of mutations in the gyrB gene asso-
ciated with quinolone resistance in clinical isolates of Neisseria gonor-

and genetic characterization of the 2008 WHO Neisseria gonorrhoeae re-
ference strain panel intended for global quality assurance and quality con-
trol of gonococcal antimicrobial resistance surveillance for public health 